2,598
Views
16
CrossRef citations to date
0
Altmetric
Research Paper

Neuronal pentraxin II (NPTX2) hypermethylation promotes cell proliferation but inhibits cell cycle arrest and apoptosis in gastric cancer cells by suppressing the p53 signaling pathway

, , &
Pages 1311-1323 | Received 29 Dec 2020, Accepted 07 Apr 2021, Published online: 25 Apr 2021

References

  • Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
  • Nagaraja AK, Kikuchi O, Bass AJ. Genomics and targeted therapies in gastroesophageal adenocarcinoma. Cancer Discov. 2019;9(12):1656–1672.
  • Ushijima T, Sasako M. Focus on gastric cancer. Cancer Cell. 2004;5(2):121–125.
  • Van Cutsem E, Sagaert X, Topal B, et al. Gastric cancer. Lancet. 2016;388(10060):2654–2664.
  • Shah MA. Update on metastatic gastric and esophageal cancers. J Clin Oncol. 2015;33(16):1760–1769.
  • Ebrahimi V, Soleimanian A, Ebrahimi T, et al. Epigenetic modifications in gastric cancer: focus on DNA methylation. Gene. 2020;742:144577.
  • Kobayashi H, Akasaka J, Koike N, et al. Preeclampsia as a parental epigenetic disease. Clin Exp Obstet Gynecol. 2018;45(4):493–502.
  • Choi IS, Wu TT. Epigenetic alterations in gastric carcinogenesis. Cell Res. 2005;15(4):247–254.
  • Choi SJ, Jung SW, Huh S, et al. Alteration of DNA methylation in gastric cancer with chemotherapy. J Microbiol Biotechnol. 2017;27(8):1367–1378.
  • Parry A, Rulands S, Reik W. Active turnover of DNA methylation during cell fate decisions. Nat Rev Genet. 2021;22(1):59–66.
  • Klutstein M, Nejman D, Greenfield R, et al. DNA methylation in cancer and aging. Cancer Res. 2016;76(12):3446–3450.
  • Tahara T, Arisawa T. DNA methylation as a molecular biomarker in gastric cancer. Epigenomics. 2015;7(3):475–486.
  • Tamura G. Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer. World J Gastroenterol. 2006;12(2):192–198.
  • Sugita H, Iida S, Inokuchi M, et al. Methylation of BNIP3 and DAPK indicates lower response to chemotherapy and poor prognosis in gastric cancer. Oncol Rep. 2011;25(2):513–518.
  • Higashimori A, Dong Y, Zhang Y, et al. Forkhead box F2 suppresses gastric cancer through a novel FOXF2-IRF2BPL-β-Catenin signaling axis. Cancer Res. 2018;78(7):1643–1656.
  • Koch A, Joosten SC, Feng Z, et al. Analysis of DNA methylation in cancer: location revisited. Nat Rev Clin Oncol. 2018;15(7):459–466.
  • Hsu YC, Perin MS. Human neuronal pentraxin II (NPTX2): conservation, genomic structure, and chromosomal localization. Genomics. 1995;28(2):220–227.
  • Swanson A, Wolf T, Sitzmann A, et al. Neuroinflammation in Alzheimer’s disease: pleiotropic roles for cytokines and neuronal pentraxins. Behav Brain Res. 2018;347:49–56.
  • Tang CZ, Zhang DF, Yang JT, et al. Overexpression of microRNA-301b accelerates hippocampal microglia activation and cognitive impairment in mice with depressive-like behavior through the NF-κB signaling pathway. Cell Death Dis. 2019;10(4):316.
  • Chang S, Bok P, Tsai CY, et al. NPTX2 is a key component in the regulation of anxiety. Neuropsychopharmacology. 2018;43(9):1943–1953.
  • Xiao MF, Xu D, Craig MT, et al. NPTX2 and cognitive dysfunction in Alzheimer’s disease. eLife. 2017;6:e23798.
  • Xu C, Tian G, Jiang C, et al. NPTX2 promotes colorectal cancer growth and liver metastasis by the activation of the canonical Wnt/β-catenin pathway via FZD6. Cell Death Dis. 2019;10(3):217.
  • Bartolini A, Di Paolo D, Noghero A, et al. The neuronal pentraxin-2 pathway is an unrecognized target in human neuroblastoma, which also offers prognostic value in patients. Cancer Res. 2015;75(20):4265–4271.
  • Von Roemeling CA, Radisky DC, Marlow LA, et al. Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4. Cancer Res. 2014;74(17):4796–4810.
  • Singh N, Rashid S, Rashid S, et al. Clinical significance of promoter methylation status of tumor suppressor genes in circulating DNA of pancreatic cancer patients. J Cancer Res Clin Oncol. 2020;146(4):897–907.
  • Zhang L, Gao J, Li Z, et al. Neuronal pentraxin II (NPTX2) is frequently down-regulated by promoter hypermethylation in pancreatic cancers. Dig Dis Sci. 2012;57(10):2608–2614.
  • Zhang L, Gao J, Li L, et al. The neuronal pentraxin II gene (NPTX2) inhibit proliferation and invasion of pancreatic cancer cells in vitro. Mol Biol Rep. 2011;38(8):4903–4911.
  • Shukla S, Pia Patric IR, Thinagararjan S, et al. A DNA methylation prognostic signature of glioblastoma: identification of NPTX2-PTEN-NF-κB nexus. Cancer Res. 2013;73(22):6563–6573.
  • Sato N, Fukushima N, Maitra A, et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res. 2003;63(13):3735–3742.
  • Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene. 2005;24(17):2899–2908.
  • Issaeva N. p53 signaling in cancers. Cancers (Basel). 2019;11:3.
  • Khatoon E, Deka M, Saikia KK, et al. Clinical significance of β-catenin, hTERT, p53, and Wnt7A as biomarkers for ovarian cancer. Eur J Gynaecological Oncol. 2020;41(2):181–187.
  • Karimian A, Ahmadi Y, Yousefi B. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair (Amst). 2016;42:63–71.
  • Nakanishi A, Kitagishi Y, Ogura Y, et al. The tumor suppressor PTEN interacts with p53 in hereditary cancer (review). Int J Oncol. 2014;44(6):1813–1819.
  • Trotman LC, Pandolfi PP. PTEN and p53: who will get the upper hand? Cancer Cell. 2003;3(2):97–99.